SRPT Sarepta Therapeutics Inc.

124.16
-3.18  -3%
Previous Close 127.34
Open 128.55
Price To Book 6.83
Market Cap 9,206,944,251
Shares 74,153,868
Volume 1,011,001
Short Ratio
Av. Daily Volume 971,265

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing due mid-2019.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 dosing to be completed 2Q 2019.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Phase 1 trial safety and dosing insight due by end of 2019 or 1Q 2020.
SRP-5051 - PPMO
Duchenne muscular dystrophy
PDUFA date under priority review August 19, 2019 .
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 data February 27, 2019 noted mean of 51% beta-sarcoglycan positive fibers.
MYO-101
Duchenne muscular dystrophy - LGMD2E
Phase 2/3 initiation of dosing announced February 14, 2019.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)